Clinical TrialID 2545
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
NCT00382811
Fallopian Tube Cancer|Peritoneal Neoplasms|Ovarian Cancer
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 2545
- Evidence Id
- 2545
- Core Evidence Id
- 2545
- Source Clinical Trial Id
- 2525
- Herb2 Clinical Trial Id
- HBCT002525
- Nct Id
- NCT00382811
- Title
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 3
- Study Result
- No
- Study Condition
- Fallopian Tube Cancer|Peritoneal Neoplasms|Ovarian Cancer
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: phenoxodiol|DRUG: carboplatin|DRUG: placebo
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Quadruple
- Intervention Purpose
- Treatment
- Gender
- Female
- Age
- Adult, Older_Adult
- Enrollment
- 142
- Outcome Measure
- The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death, Progression Free Survival
- Sponsor Collaborator
- MEI Pharma, Inc.
- Funded By
- INDUSTRY
- Location
- Arizona Clinical Research Center, Inc., Tuscon, Arizona, 85715, United States|Glendale Adventist, Glendale, California, 91206, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, 90027, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Gynecology Oncology Associates, Newport Beach, California, 92663, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States|Hematology Oncology, PC (Carl and Dorothy Bennett Cancer Center), Stamford, Connecticut, 06902, United States|Gynecologic Oncology Associates, Pembroke Pines, Florida, 33028, United States|Piedmont Hospital, Atlanta, Georgia, 30309, United States|Medical College of Georgia Cancer Center, Augusta, Georgia, 30912, United States|Associates in Women's Health, Wichita, Kansas, 67214, United States|Hematology and Oncology Specialists, LLC, Metairie, Louisiana, 70006, United States|Greater Baltimore Medical Centre, Baltimore, Maryland, 21204, United States|Gynecologic Oncology of West Michigan, Grand Rapids, Michigan, 49546, United States|Providence Hospital and Medical Centers, Southfield, Michigan, 48075, United States|The Center for Cancer & Hematological Disease, Cherry Hill, New Jersey, 08003, United States|Jersey Shore Medical Center, Neptune, New Jersey, 07754, United States|The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, 87131-0001, United States|Schwartz Gynecologic Oncology, Brightwaters, New York, 11718, United States|New York Downtown Hospital, New York, New York, 10038, United States|University of Rochester Gynecologic Oncology Associates, Rochester, New York, 14620, United States|Carolinas Medical Center, Charlotte, North Carolina, 28204, United States|Brody School of Medical at East Carolina University, Greenville, North Carolina, 27834, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|Gabrail Cancer Center, Canton, Ohio, 44718, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States|OSU James Cancer Hospital & Solove Research Institute, Columbus, Ohio, 43210, United States|Miami Valley Hospital, Dayton, Ohio, United States|Chattanooga GYN Oncology, Chattanooga, Tennessee, 37403, United States|Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, 37403, United States|Hall and Martin MDS, P.C., Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Hope Cancer Clinic, Brownsville, Texas, 78526, United States|University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center, Dallas, Texas, 75390, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Northern Virginia Pelvic Surgery Associates, Annadale, Virginia, 22003, United States|Virginia Mason Medical Center Department of Hematology/Oncology, Seattle, Washington, 98101, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, 2065, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Mater Adult Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|UZ Antwerpen, Edegem, 2650, Belgium|UZ Leuven, Leuven, 3000, Belgium|IEO- Istituto Europeo di Oncologia, Milano, 20141, Italy|Istitutio Fisioterapici Ospitaleri, Roma, 00144, Italy|Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie Oddzial Onkologii Ginekologicznej, Bialystok, 15-027, Poland|Ackademickie Centrum Kliniczne-Szpital, Akademii Medycznej w Gdansku, Gdansk, 80-402, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie, Oddzial w Gliwicach, Gliwice, 44-101, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie Oddzial w Krakowie Klinika Ginekologii Onkologicznej, Krakow, 31-115, Poland|Centrum Onkologii Ziemi, Lublin, 20-090, Poland|Ginekologiczno - Polozniczy Szpital Kliniczny AM im. K. Marcinkowskiego w Poznaniu SPZOZ Klinika Onkologii Ginekologicznej, Poznan, 60-535, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie Klinika Nowotworow Narzadow Plciowych Kobiecych, Warszawa, 02-781, Poland|Hospital Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital General Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, 08036, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Yeovil District Hospital, Yeovil, Somerset, BA21 4AT, United Kingdom|Cancer Research UK Clinical Trials Unit Old Clinical Investigations Building, Birmingham, B18 7QH, United Kingdom|Ninewells Hospital, Dundee, DD1 9SY, United Kingdom|Edinburgh Cancer Research Centre Western General Hospital, Edinburgh, EH4 2XR, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YH, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Hammersmith Hospital, London, W12 0HS, United Kingdom|Cancer Research UK & UCL Cancer Trials Center, London, W1T 4TJ, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom|Clatterbridge Centre for Oncology, Wirral, CH63 4JY, United Kingdom
- Other Id
- NV06-0039
- Start Date
- 2006-10
- Primary Completion Date
- 2009-04
- Completion Date
- 2011-04
- First Posted
- 2006-10-02
- Results First Posted
- Last Update Posted
- 2016-07-18
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00382811
- Title Cn
- Title En
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
- Bilingual Status
- semi_complete